Knowledge Creation at Eisai Co., Ltd. Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Eisai 1990s focus: Shift from commodity drugs to specialized therapeutic areas (oncology, neurology).
• R&D Investment: Significant increase in R&D spending as a percentage of sales to fuel innovation-led growth.
• Profitability: Historically dependent on blockbuster drugs; moving toward a model of continuous knowledge creation to mitigate patent cliffs.

Operational Facts

• Philosophy: Human Health Care (hhc) — a commitment to patients and their families.
• Knowledge Management: Implementation of SECI model (Socialization, Externalization, Combination, Internalization).
• Organizational Structure: Creation of the Knowledge Creation Department to institutionalize tacit knowledge sharing.
• Process: Researchers required to spend time with patients and medical professionals to gain direct insight into unmet needs.

Stakeholder Positions

• Haruo Naito (CEO): Architect of the hhc philosophy; views knowledge creation as the primary driver of competitive advantage.
• Researchers: Initially resistant to the requirement of spending significant time outside the laboratory; shifted perspective as patient insights directly influenced drug development success.

Information Gaps

• Specific longitudinal data on the ROI of the Knowledge Creation Department versus traditional R&D models.
• Metrics regarding the speed of product development cycles post-implementation of the SECI model.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Can a pharmaceutical firm institutionalize the conversion of tacit knowledge into proprietary drug development without diluting scientific rigor?

Structural Analysis

• Value Chain: Eisai moved the primary locus of innovation from the bench to the bedside. By embedding researchers in the patient experience, they optimized the front end of the value chain (target identification).
• Jobs-to-be-Done: The patient’s job is not just to take a drug, but to regain quality of life. Eisai’s focus on hhc aligns the firm with the patient’s desired outcome rather than just the clinical efficacy of a compound.

Strategic Options

• Option 1: The Patient-Centric Innovation Model (Current Path): Institutionalize the SECI process across all global regions. Trade-offs: High cultural investment, risk of slowing down early-stage research. Requirements: Sustained leadership commitment and cross-functional rotation.
• Option 2: The Open Innovation Partnership: Shift focus to licensing external discoveries and focus internal resources only on clinical trials. Trade-offs: Faster time-to-market, loss of unique internal knowledge advantage. Requirements: Strong M&A and business development teams.

Preliminary Recommendation

Maintain the Patient-Centric Innovation Model. The pharmaceutical industry is shifting toward personalized medicine; internalizing deep patient insights is a durable barrier to entry that competitors cannot replicate through simple licensing.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

• Phase 1 (Months 1-6): Standardize the patient-immersion program across all R&D centers. Establish KPIs linking patient insights to project selection.
• Phase 2 (Months 7-18): Integrate SECI-based knowledge management into digital R&D platforms to ensure global accessibility of tacit insights.
• Phase 3 (Months 19+): Evaluate the conversion rate of patient-inspired concepts into clinical trials.

Key Constraints

• Cultural Inertia: Senior scientists may view patient immersion as a distraction from pure research.
• Measurement Difficulty: Quantifying the impact of knowledge creation on long-term drug pipeline health is notoriously difficult.

Risk-Adjusted Implementation

Implement a pilot rotation program. Instead of a firm-wide mandate, start with the oncology unit. If successful, scale to neurology. This limits exposure to disruption while demonstrating tangible impact on pipeline quality.

4. Executive Review and BLUF (Executive Critic)

BLUF

Eisai’s strategy is not a management exercise; it is a fundamental reconfiguration of the R&D function. By forcing researchers to engage with patients, Naito has replaced abstract hypothesis-generation with direct observation. This is the correct path. In a market where clinical compounds are increasingly commoditized, the ability to define the problem better than the competition is the only sustainable advantage. The plan is approved, provided that the company treats patient insights as hard data rather than anecdotal evidence.

Dangerous Assumption

The analysis assumes that researchers who are excellent at bench science possess the interpersonal capability to extract actionable insights from patients. This requires a specific skill set that may be absent in the current talent pool.

Unaddressed Risks

• Regulatory Compliance: Intensive, unstructured interactions between researchers and patients could inadvertently create compliance or ethical conflicts in certain jurisdictions.
• Knowledge Siloing: The SECI model relies on individuals. If key knowledge-creators leave, the organization risks losing the tacit knowledge that has not yet been codified.

Unconsidered Alternative

The team failed to consider a hybrid model where a dedicated clinical-liaison team acts as a bridge, collecting insights and translating them into technical requirements for researchers, rather than requiring every scientist to be an ethnographer.

Verdict: APPROVED FOR LEADERSHIP REVIEW.